MK-677 (Ibutamoren)

Overview

MK-677, commonly known as ibutamoren, is a non-peptide compound that acts as a growth hormone secretagogue — meaning it prompts the body to secrete more of its own growth hormone rather than supplying growth hormone directly. It works by mimicking ghrelin, the so-called hunger hormone, at its receptor.

Unlike most compounds in this category, MK-677 is a small molecule that is orally active, so it is studied as an oral agent rather than an injectable. In clinical research it has been shown to raise both growth hormone and IGF-1 levels, and it is often discussed in the context of body composition, recovery, and age-related decline in growth hormone.

MK-677 has been investigated in human trials, including studies in older adults and in Alzheimer’s disease, but it has not been approved for therapeutic use by any major regulator. It remains an investigational compound.

How it works

MK-677 is a selective, long-acting agonist of the ghrelin (growth hormone secretagogue) receptor. By activating this receptor in the pituitary and hypothalamus, it stimulates the natural, pulsatile release of growth hormone, which in turn raises circulating IGF-1. Because it works upstream of the body’s own signaling, it is often described as amplifying an existing pathway rather than replacing it.

In studied populations, this has been reported to increase growth hormone and IGF-1 into ranges seen in younger adults, with human trials generally finding little meaningful effect on cortisol at the doses examined.

Reported benefits

• Increased fat-free (lean) mass in older adults (clinical data)
• Elevated growth hormone and IGF-1 levels
• Reported improvements in sleep quality, including slow-wave and REM sleep
• Increased appetite, which has been studied as a potential benefit in age-related weight loss

These are reported and studied effects, not guaranteed outcomes, and benefits observed in specific research populations may not generalize.

Considerations & side effects

The side effects most commonly reported with MK-677 include increased appetite, water retention, and changes in blood glucose and insulin sensitivity — the latter warranting particular attention in anyone with, or at risk of, impaired glucose tolerance. Because it raises IGF-1, its long-term effects are still being characterized.

Human data comes largely from time-limited trials, and MK-677 is not approved for human use. Product purity varies widely in the research-chemical market, and MK-677 is a substance banned in most competitive sport. It is not a substitute for evaluation and treatment by a qualified clinician.